| P50 | author | Caroline M Perry | Q62562982 |
| | Antona J Wagstaff | Q62563491 |
| P2093 | author name string | David R Goldsmith | |
| | Tim Ibbotson | |
| P2860 | cites work | Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder | Q48371331 |
| | Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current | Q48447285 |
| | Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects | Q48707574 |
| | The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services | Q50127660 |
| | Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. | Q50970308 |
| | Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. | Q52209617 |
| | Bidirectional interaction of valproate and lamotrigine in healthy subjects. | Q53984188 |
| | Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. | Q54106317 |
| | Impact of clinical variables on illness time course in mood disorders | Q60628033 |
| | Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy | Q68843632 |
| | Outcomes of add-on treatment with lamotrigine in partial epilepsy | Q70612345 |
| | Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation | Q70790738 |
| | Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases | Q71201898 |
| | Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications | Q71589843 |
| | Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study | Q71625626 |
| | Cerebroprotective effect of lamotrigine after focal ischemia in rats | Q72486597 |
| | Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis | Q72562989 |
| | Seizure severity and the quality of life | Q72852953 |
| | Saliva and serum concentration of lamotrigine in patients with epilepsy | Q73084361 |
| | Prevention by lamotrigine, MK-801 and N omega-nitro-L-arginine methyl ester of motoneuron cell death after neonatal axotomy | Q73118134 |
| | Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy | Q73794142 |
| | Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation | Q73855666 |
| | Practice guideline for the treatment of patients with bipolar disorder (revision) | Q95789383 |
| | A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group | Q28139401 |
| | Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones | Q28235930 |
| | Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey | Q28258215 |
| | The risk of suicide in patients with bipolar disorders | Q33540362 |
| | A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. | Q33844681 |
| | Suicide and bipolar disorder. | Q33926850 |
| | Reduced suicide risk during lithium maintenance treatment | Q33926872 |
| | A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders | Q33927263 |
| | Lamotrigine. A review of its use in childhood epilepsy | Q34006439 |
| | Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans | Q34187258 |
| | Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy | Q34306763 |
| | Comparative efficacy and tolerability of drug treatments for bipolar disorder | Q34387550 |
| | MRI findings in patients with affective disorder: a meta-analysis | Q34439133 |
| | Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats | Q34479439 |
| | Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? | Q34726336 |
| | Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy | Q34733759 |
| | Lamotrigine in the treatment of bipolar disorder | Q34974841 |
| | Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. | Q35005642 |
| | Bipolar depression: management options | Q35017636 |
| | Safety and tolerability of lamotrigine for bipolar disorder | Q35645906 |
| | The effects of lamotrigine on the pharmacokinetics of lithium | Q36055287 |
| | Neurochemical and Behavioral Aspects of Lamotrigine | Q36541033 |
| | Clinical pharmacology of lamotrigine | Q36923401 |
| | Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders | Q40661158 |
| | Lamotrigine clinical pharmacokinetics | Q40720372 |
| | Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy | Q40932340 |
| | Clinical pharmacokinetics of newer antiepileptic drugs. Lamotrigine, vigabatrin, gabapentin and oxcarbazepine | Q41101288 |
| | Pharmacokinetic interactions of the new antiepileptic drugs | Q41192725 |
| | Lamotrigine: pharmacokinetics | Q41681413 |
| | Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam | Q41969456 |
| | Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder | Q42605435 |
| | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. | Q42613693 |
| | Lamotrigine induced selective changes in 5-HT(1A) receptor mediated response in rat brain | Q43855460 |
| | A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder | Q44403599 |
| | Lamotrigine protects against kainate but not ibotenate lesions in rat striatum | Q44451689 |
| | The long-term natural history of the weekly symptomatic status of bipolar I disorder | Q46317822 |
| | A calcium antagonistic effect of the new antiepileptic drug lamotrigine | Q46388977 |
| | Effects of lamotrigine on the 5-HT1A receptor function in healthy human males | Q48020132 |
| | Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents | Q48122183 |
| | Lamotrigine concentrations in human serum, brain tissue, and tumor tissue | Q48296950 |
| | Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action | Q48303242 |
| | An electrophysiological analysis of the protective effects of felbamate, lamotrigine, and lidocaine on the functional recovery from in vitro ischemia in rat neocortical slices | Q48344227 |
| P433 | issue | 19 | |
| P921 | main subject | bipolar disorder | Q131755 |
| | lamotrigine | Q410346 |
| P304 | page(s) | 2029-2050 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Lamotrigine: a review of its use in bipolar disorder | |
| P478 | volume | 63 | |